PT  - JOURNAL ARTICLE
AU  - FitzGerald, Richard
AU  - Dickinson, Laura
AU  - Else, Laura
AU  - Fletcher, Thomas
AU  - Hale, Colin
AU  - Amara, Alieu
AU  - Walker, Lauren
AU  - Penchala, Sujan Dilly
AU  - Lyon, Rebecca
AU  - Shaw, Victoria
AU  - Greenhalf, William
AU  - Lavelle-Langham, Lara
AU  - Reynolds, Helen
AU  - Painter, Wendy
AU  - Holman, Wayne
AU  - Ewings, Sean
AU  - Griffiths, Gareth
AU  - Khoo, Saye
TI  - Pharmacokinetics of ß-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
AID  - 10.1101/2021.12.06.21267342
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.06.21267342
4099  - http://medrxiv.org/content/early/2021/12/07/2021.12.06.21267342.short
4100  - http://medrxiv.org/content/early/2021/12/07/2021.12.06.21267342.full
AB  - Background Molnupiravir, an orally administered prodrug of the broadly active, direct-acting antiviral, ribonucleoside analogue ß-d-N4-hydroxycytidine (NHC) is a promising COVID-19 drug candidate. We characterised the pharmacokinetics of NHC in saliva, nasal secretions and tears of patients enrolled in the phase I AGILE trial (NCT04746183) to understand its potential in preventing infection and transmission.Methods Patients with PCR-confirmed SARS-CoV-2 infection, within 5 days of symptom onset with mild-to-moderate disease were randomised to oral molnupiravir 300, 600 or 800 mg twice daily or placebo. Plasma and non-plasma (saliva, nasal secretions and tears) samples were collected at pre-dose, 0.5, 1, 2, and 4 hours post-dose on study days 1 and 5 and molnupiravir and NHC measured by LC/MS with a lower limit of quantification of 2.5 ng/mL in all matrices. Pharmacokinetic parameters were determined by noncompartmental methods and non-plasma:plasma ratios (RNP:P; based on AUC0-4) calculated.Results Twelve participants (n=4 per dosing arm; 75% female) completed the study. NHC Tmax ranged between 1.00-4.00 hours for saliva (n=21) and nasal swabs (n=22) and 0.50-4.00 hours (n=17) for tears compared to 1.00-2.00 hours for plasma (n=19). Median (range) saliva RNP:P pooled across doses was 0.03 (0.01-0.11); n=16. RNP:P for nasal secretions and tears were 0.21 (0.05-0.73); n=17 and 0.22 (0.09-1.05); n=12, respectively. Non-plasma and plasma concentrations were significantly correlated (p<0.0001).Conclusion These data provide encouraging information regarding the distribution of NHC at sites of viral transmission and have important implications for prophylactic coverage.Competing Interest StatementSK has received research funding from ViiV Healthcare, Gilead Sciences, and Merck for the Liverpool HIV Drug Interactions programme and for clinical studies unrelated to the submitted work. GG has received funding from Jannsen-Cilag, Novartis, Astex, Roche, Heartflow, Bristol Myers Squibb, BioNtech; grants and personal fees from AstraZeneca; and personal fees from Celldex, unrelated to the submitted work. WG has received funding from the Wellcome Trust. WH is a cofounder, owner and advisor of/to Ridgeback Biotherapeutics. WP is employed by Ridgeback Biotherapeutics.Clinical TrialNCT04746183Funding StatementThis work was funded by the University of Liverpool. The AGILE platform infrastructure is supported by the Medical Research Council (grant number MR/V028391/1) and the Wellcome Trust (grant number 221590/Z/20/Z). AGILE CST-2 molnupiravir trial was supported by Ridgeback Biotherapeutics. We acknowledge National Institute for Health Research (NIHR) infrastructure funding for the Liverpool Clinical Research Facility and the Southampton Clinical Trials Unit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the UK Medicines and Healthcare product Regulatory Agency (MHRA; EudraCT 2020 001860 27) and West Midlands Edgbaston Research Ethics Committee (20/WM/0136) and all individuals provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed and presented in the manuscript are available upon reasonable request to the authors